How does the Medical Devices Advisory Committee (MDAC) work? DM: FDA uses committees and panels to obtain independent expert advice on scientific, technical and policy matters. MDAC consists of 18 panels. With the exception of the Dental Products Panel and the Medical Devices Dispute Resolution Panel, each panel consists of a maximum of seven standing voting members (including the chair) and two nonvoting members (a consumer representative and an industry representative). The panels advise the commissioner regarding recommended classification or reclassification of devices into one of three regulatory categories; advise on any possible risks to health associated with the use of devices; advise on formulation of product development protocols; review pre-market approval applications for medical devices; review guidelines and guidance documents; recommend exemption of certain devices from the application of portions of the act; advise on the necessity to ban a device; and respond to requests from the agency to review and make recommendations on specific issues or problems concerning the safety and effectiveness of devices.


Each panel, according to its specialty area, may also make appropriate recommendations to the commissioner on issues relating to the design of clinical studies regarding the safety and effectiveness of marketed and investigational devices. The committees are advisory—they provide their expertise and recommendations—but final decisions are made by FDA.


The CSDP and the Radiological Devices Panel are likely to be of most interest to IRs. Scientific member nominees must be technically qualified experts in their field with experience interpreting complex data. Potential candidates must provide detailed information concerning such matters as financial holdings, employment and research grants and/or contracts in order to permit evaluation of possible sources of conflict of interest.


Dr. Khaja, how did you become involved in the CDRH? Minaj S. Khaja, MD, MBA, FSIR: When I was nominated for the role on the CSDP in late 2020, I was very excited about the potential to represent IRs in a multidisciplinary fashion. In this role, I felt I would be able to harmonize my clinical experience as well as research background in advocating for patient safety.


After completing several screening documents and a virtual interview, I was accepted onto the panel. Since joining as a special government employee in 2020, I’ve participated in two separate advisory panels.


What does your work with the MDAC entail? MK: My work, and that of the other panelists, entails a thorough review of a specific issue with a device or devices that are under review by the FDA. These issues may be device-specific or related to a pathological process (AAA-EVAR). We review a body of literature provided by the FDA as well as studies completed by the vendor. We then hear presentations from different stakeholders including the vendor, physicians in support, those not in support, patient advocates and the FDA, among others. Our goal on the advisory panel is to conclude whether the body of evidence is supportive of the device and whether it is safe and effective for use in the general patient population.


We then have a confidential group discussion and give our opinion in the matter to the FDA representatives. They then take our opinions and reach their final decision, based on their internal review and analysis. It is a very robust process of reviewing a problem, analyzing data and determining the next course of action.


I think work like this is very important to participate in, especially for members of the radiology and IR communities. I find it very fulfilling and look forward to participating more in the future.


How can interested IRs get involved in the CDRH? DM: The CDRH regularly has openings for full-time or part-time physicians. They understand that leveraging


workplace flexibilities is critical to recruit and retain a talented workforce. Almost all OPEQ physicians have been working remotely since March 2020, including many at locations outside of the D.C. metro area. Full-time employment is on a flexible, 80-hour biweekly basis and provides substantial benefits, including health insurance, life insurance, vacation time, sick leave, 11 federal holidays and a retirement plan.


CDRH offers a Medical Device Fellowship that was established to increase the range and depth of collaborations between CDRH and the outside scientific community. The program offers short- and long-term fellowship opportunities for individuals interested in learning about the regulatory process and sharing their knowledge and experience with medical devices from the relatively simple to the highly complex.


IRs can also participate on MDAC panels. Anyone can nominate one or more qualified persons for an opening on one or more of the advisory committees or advisory panels. Self-nominations are also welcome.


Are there any requirements or qualifications required for IRs who would like to become involved with the CDRH? DM: Permanent FDA employees must be U.S. citizens. Staff fellows, who are hired for a period of limited duration, may be permanent residents. Physicians must have an active medical license in any U.S. state, Washington, D.C., Puerto Rico, or a U.S. territory. FDA employees, their spouses and minor children are prohibited from holding financial interests, like stock, in certain businesses regulated by FDA. This includes many companies working in the drug, biologic, medical device, food and tobacco industries, among others. There are different rules for MDAC panel members. Potential panel members are also asked to provide detailed information concerning such matters as financial holdings, employment, and research grants and/or contracts in order to permit evaluation of possible sources of conflict of interest.


sirweb.org/irq | 21


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48